BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dr. Andrew Luster, Chief of the Division of Rheumatology, Allergy, and Immunology at Massachusetts General Hospital (MGH), and Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a drug discovery and development company focused on therapeutics targeting Toll-like Receptors (TLR), have received a Cooperative Research Grant from the Massachusetts Life Sciences Center (MLSC). Under the collaboration between Dr. Luster and Idera, Idera’s novel TLR antagonist candidates will be studied as potential therapeutic agents for autoimmune diseases such as lupus.
